Canopy Growth (FRA:11L) Moat Score: 5/10 (As of Jul. 08, 2026)


FRA:11L Canopy Growth Corp FRA:11L
59 GF Score
Price €0.84
GF Value €0.65
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Canopy Growth Moat Score?

Canopy Growth FRA:11L -0.64% 59 Moat Score is 5 as of Jul. 08, 2026. GuruFocus rates FRA:11L with a GF Score™ of 59/100 and a GF Value™ of €0.65 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Canopy Growth ranks better than 94.67% on this metric.

Canopy Growth has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Canopy Growth has Narrow Moat: Canopy Growth has a solid narrow moat due to its strong brand in the cannabis industry and significant market share. However, it faces regulatory challenges and intense competition, and lacks proprietary technology or significant cost advantages to qualify for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Canopy Growth might have Narrow Moat - Solid narrow moat.

Canopy Growth  (FRA:11L) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Canopy Growth Moat Score Related Terms

FRA:11L vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canopy Growth Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Moat Score distribution charts can be found below:

* The bar in red indicates where Canopy Growth's Moat Score falls into.


FRA:11L
59GF Score
Canopy Growth Corp FRA:11L
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Canopy Growth (FRA:11L) has a Moat Score of 5 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Canopy Growth ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Canopy Growth's Moat Score too high?
Canopy Growth's current Moat Score is 5. Based on the distribution chart, Canopy Growth ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #55 out of 1031 companies for Moat Score. This places Canopy Growth in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Canopy Growth's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (FRA:11L) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €0.84 — trading 29.7% above its estimated fair value. The current Moat Score is 5. Canopy Growth's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Canopy Growth (FRA:11L), the current Moat Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canopy Growth (FRA:11L) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of €0.84 is trading 29.7% above its estimated GF Value™ of €0.65. GuruFocus considers Canopy Growth to be Modestly Overvalued.

Key valuation signals for FRA:11L:

  • Moat Score: 5
  • GF Value™: €0.65 vs. price of €0.84 (29.7% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score

Get the complete analysis for FRA:11L

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.84
Price
€0.65
GF Value